Cargando…

PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses

PURPOSE: Antigen-presenting cells (APCs) are powerful tools to expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but suffer from time-consuming generation and biosafety concerns raised by live cells. Alternatively, the cell-free artificial antigen-presenting cells (aAPCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Shilong, Jin, Xiaoxiao, Zhang, Lei, Zhao, Chen, Ding, Yan, Ang, Qianqian, Khaidav, Odontuya, Shen, Chuanlai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459144/
https://www.ncbi.nlm.nih.gov/pubmed/31040669
http://dx.doi.org/10.2147/IJN.S195828
_version_ 1783410144229457920
author Song, Shilong
Jin, Xiaoxiao
Zhang, Lei
Zhao, Chen
Ding, Yan
Ang, Qianqian
Khaidav, Odontuya
Shen, Chuanlai
author_facet Song, Shilong
Jin, Xiaoxiao
Zhang, Lei
Zhao, Chen
Ding, Yan
Ang, Qianqian
Khaidav, Odontuya
Shen, Chuanlai
author_sort Song, Shilong
collection PubMed
description PURPOSE: Antigen-presenting cells (APCs) are powerful tools to expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but suffer from time-consuming generation and biosafety concerns raised by live cells. Alternatively, the cell-free artificial antigen-presenting cells (aAPCs) have been rapidly developed. Nanoscale aAPCs are recently proposed owing to their superior biodistribution and reduced embolism than conventional cell-sized aAPCs, but pose the challenges: easier cellular uptake and smaller contact surface area with T cells than the cell-sized counterparts. This study aimed to fabricate a new “stealth” nano-aAPCs with microscale contact surface area to minimize cellular uptake and activate antigen-specific T cells by combination uses of ellipsoidal stretch, PEGylation, and self-marker CD47-Fc conjugation. METHODS: The spherical polylactic-co-glycolic acid nanoparticles were fabricated using a double-emulsion method, and then stretched twofold using film-stretching procedure followed by PEGylation and co-coupling with CD47-Fc, H-2K(b)/TRP2(180-188)-Ig dimers, and anti-CD28. The resulting PEGylated and CD47-conjugated nanoellipsoidal aAPCs (EaAPC(PEG/CD47)) were co-cultured with macrophages or spleen lymphocytes and also infused into melanoma-bearing mice. The in vitro and in vivo effects were evaluated and compared with the nanospherical aAPCs (SaAPC), nanoellipsoidal aAPCs (EaAPC), or PEGylated nanoellipsoidal aAPC (EaAPC(PEG)). RESULTS: EaAPC(PEG/CD47) markedly reduced cellular uptake in vitro and in vivo, as compared with EaAPC(PEG), EaAPC, SaAPC, and Blank-NPs and expanded naïve TRP2(180-188)-specific CD8(+) T cells in the co-cultures with spleen lymphocytes. After three infusions, the EaAPC(PEG/CD47) showed much stronger effects on facilitating TRP2(180-188)-specific CD8(+) T-cell proliferation, local infiltration, and tumor necrosis in the melanoma-bearing mice and on inhibiting tumor growth than the control aAPCs. CONCLUSION: The superimposed or synergistic effects of ellipsoidal stretch, PEGylation, and CD47-Fc conjugation minimized cellular uptake of nano-aAPCs and enhanced their functionality to expand antigen-specific T cells and inhibit tumor growth, thus suggesting a more valuable strategy to design “stealth” nanoscale aAPCs suitable for tumor active immunotherapy.
format Online
Article
Text
id pubmed-6459144
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64591442019-04-30 PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses Song, Shilong Jin, Xiaoxiao Zhang, Lei Zhao, Chen Ding, Yan Ang, Qianqian Khaidav, Odontuya Shen, Chuanlai Int J Nanomedicine Original Research PURPOSE: Antigen-presenting cells (APCs) are powerful tools to expand antigen-specific T cells ex vivo and in vivo for tumor immunotherapy, but suffer from time-consuming generation and biosafety concerns raised by live cells. Alternatively, the cell-free artificial antigen-presenting cells (aAPCs) have been rapidly developed. Nanoscale aAPCs are recently proposed owing to their superior biodistribution and reduced embolism than conventional cell-sized aAPCs, but pose the challenges: easier cellular uptake and smaller contact surface area with T cells than the cell-sized counterparts. This study aimed to fabricate a new “stealth” nano-aAPCs with microscale contact surface area to minimize cellular uptake and activate antigen-specific T cells by combination uses of ellipsoidal stretch, PEGylation, and self-marker CD47-Fc conjugation. METHODS: The spherical polylactic-co-glycolic acid nanoparticles were fabricated using a double-emulsion method, and then stretched twofold using film-stretching procedure followed by PEGylation and co-coupling with CD47-Fc, H-2K(b)/TRP2(180-188)-Ig dimers, and anti-CD28. The resulting PEGylated and CD47-conjugated nanoellipsoidal aAPCs (EaAPC(PEG/CD47)) were co-cultured with macrophages or spleen lymphocytes and also infused into melanoma-bearing mice. The in vitro and in vivo effects were evaluated and compared with the nanospherical aAPCs (SaAPC), nanoellipsoidal aAPCs (EaAPC), or PEGylated nanoellipsoidal aAPC (EaAPC(PEG)). RESULTS: EaAPC(PEG/CD47) markedly reduced cellular uptake in vitro and in vivo, as compared with EaAPC(PEG), EaAPC, SaAPC, and Blank-NPs and expanded naïve TRP2(180-188)-specific CD8(+) T cells in the co-cultures with spleen lymphocytes. After three infusions, the EaAPC(PEG/CD47) showed much stronger effects on facilitating TRP2(180-188)-specific CD8(+) T-cell proliferation, local infiltration, and tumor necrosis in the melanoma-bearing mice and on inhibiting tumor growth than the control aAPCs. CONCLUSION: The superimposed or synergistic effects of ellipsoidal stretch, PEGylation, and CD47-Fc conjugation minimized cellular uptake of nano-aAPCs and enhanced their functionality to expand antigen-specific T cells and inhibit tumor growth, thus suggesting a more valuable strategy to design “stealth” nanoscale aAPCs suitable for tumor active immunotherapy. Dove Medical Press 2019-04-08 /pmc/articles/PMC6459144/ /pubmed/31040669 http://dx.doi.org/10.2147/IJN.S195828 Text en © 2019 Song et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Song, Shilong
Jin, Xiaoxiao
Zhang, Lei
Zhao, Chen
Ding, Yan
Ang, Qianqian
Khaidav, Odontuya
Shen, Chuanlai
PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title_full PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title_fullStr PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title_full_unstemmed PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title_short PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses
title_sort pegylated and cd47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor t-cell responses
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459144/
https://www.ncbi.nlm.nih.gov/pubmed/31040669
http://dx.doi.org/10.2147/IJN.S195828
work_keys_str_mv AT songshilong pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT jinxiaoxiao pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT zhanglei pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT zhaochen pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT dingyan pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT angqianqian pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT khaidavodontuya pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses
AT shenchuanlai pegylatedandcd47conjugatednanoellipsoidalartificialantigenpresentingcellsminimizephagocytosisandaugmentantitumortcellresponses